We use essential cookies and third-party cookies for content.

Deutsche Tageszeitung - US FDA approves Wegovy to cut risk of heart problems

US FDA approves Wegovy to cut risk of heart problems

HEALTH 08.03.2024
US FDA approves Wegovy to cut risk of heart problems
US FDA approves Wegovy to cut risk of heart problems / Photo: © AFP/File

The US Food and Drug Administration has given the green light for a popular anti-obesity drug to be used to prevent serious heart conditions for the first time, in a move likely to expand insurance coverage.

Change text size:

Wegovy, produced by Danish pharmaceutical giant Novo Nordisk, was approved "to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight," the FDA said in a statement.

The FDA's decision could be a game changer for the approximately 70 percent of American adults who it says are either obese or overweight, by potentially expanding the pool of people eligible to have their insurance cover these expensive but effective drugs.

"This patient population has a higher risk of cardiovascular death, heart attack and stroke," the director of the FDA's Division of Diabetes, Lipid Disorders and Obesity, said in a statement.

"Providing a treatment option that is proven to lower this cardiovascular risk is a major advance for public health," he added.

The recent surge in popularity of anti-obesity drugs including Wegovy and Ozempic, which mimic a gut hormone to suppress appetite, has padded the profits of the companies that make them.

In fact, Novo Nordisk, which produces both Wegovy and Ozempic, has been so profitable that it has helped to keep the Danish economy afloat, according to Danske Bank.

The pharmaceutical giant's success "is pushing overall activity levels up, while much of the rest of industry and housing construction have contracted," Heidi Schauman, the bank's global head of research, wrote in a note earlier this week.

Novo Nordisk's head of development, Martin Holst Lange, welcomed the FDA's announcement, calling it "an important milestone for people living with obesity and cardiovascular disease."

Wegovy "has the potential to prolong lives by addressing some of the leading causes of preventable deaths by reducing the risks of cardiovascular events," he said in a statement.

(W.Uljanov--DTZ)

Featured

Toddler Diagnosed With Leukemia After Symptoms Dismissed as Winter Illness

Manraj Singh Hans, now seven, was diagnosed with acute lymphoblastic leukemia in February 2023 after a prolonged period during which his early symptoms were repeatedly misdiagnosed as common infections. His parents, Narinder Singh and Parm Hans, initially dismissed signs of illness as winter fatigue before blood in the child’s diaper prompted urgent medical intervention.

American Airlines passenger falls ill and vomits on three travellers

A passenger on board an American Airlines reportedly experienced a medical episode mid-flight A morning flight from Philadelphia to Miami was thrown into disarray after a passenger reportedly vomited over three other travellers.

iPS Cell Research Accelerates Drug Discovery for ALS and Spinal Cord Injury

Researchers at Keiō University are leveraging induced pluripotent stem (iPS) cells to accelerate drug discovery for rare neurological conditions. Director Okano Hideyuki reports that human-derived cell models have enabled the rapid identification of potential treatments for amyotrophic lateral sclerosis and paved the way for regenerative therapies targeting spinal cord injuries.

Dengue Fever Expands Into High Himalayas as Climate Change Warms Nepal

As Nepal’s mountains warm, disease-bearing mosquitoes are expanding their range into high-elevation areas, bringing dengue fever to densely populated regions that were previously safe. The virus has now reached 76 of the country’s 77 districts, marking a dramatic shift in the geographic footprint of insect-borne illnesses driven by climate change and rapid urbanization.

Change text size: